Company profile
Zura Bio Limited
NASDAQ: ZURA · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 58DQ —GM —SS 44
v0.1 · 35/100 weight · pillars only
↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$68.7M
Employees
40
as of 2026-08-12
Market cap
$528.2M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$68.7M-$68.7M2025
Operating income-$75.2M-$75.2M2025
Total assets$113.9M$113.9M2025
Liabilities$12.4M$12.4M2025
Equity$101.5M$101.5M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Zura Bio Limited’s financial profile?
Zura Bio Limited earned -$68.7M in FY2025 net income.
Peers · Healthcare
Adlai Nortye Ltd.——GMR Solutions Inc.——Odyssey Therapeutics, Inc.——MapLight Therapeutics, Inc.——Nuvectis Pharma, Inc.——Eikon Therapeutics, Inc. Common Stock——Neighbors
San Diego →Key facts
CEOSandeep C. Kulkarni
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: ZURA
Employees40
IPO date2023-03-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.